A previous study examining the impact of specific DPP4 inhibition in murine cancer models has demonstrated that DPP4 inhibition not only elevates tumor CXCL10 levels but also enhances the trafficking of CXCR3+ NK cells and CD8+ T cells into tumors. The gene discussed is CXCL10; the disease is neoplasm.